June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Subfoveal Choroidal Thickness as a Predictor of Treatment Response to Anti-Vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • Hyesun Kim
    Department of Ophthalmology, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea (the Republic of)
  • Hyun Ju Park
    Department of Ophthalmology, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea (the Republic of)
  • SungChul Lee
    Department of Ophthalmology, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea (the Republic of)
  • Christopher Seungkyu Lee
    Department of Ophthalmology, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships Hyesun Kim, None; Hyun Ju Park, None; SungChul Lee, None; Christopher Seungkyu Lee, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5350. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hyesun Kim, Hyun Ju Park, SungChul Lee, Christopher Seungkyu Lee; Subfoveal Choroidal Thickness as a Predictor of Treatment Response to Anti-Vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5350.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To investigate whether subfoveal choroidal thickness predicted treatment responses to anti-vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV).

 
Methods
 

Retrospective observation case series. This study included 66 eyes from 60 patients who were diagnosed with new-onset PCV for a minimum follow-up of 6 months. The included patients received 3 monthly intravitreal injections of 0.5 mg ranibizumab or 1.25 mg bevacizumab at baseline, month 1, and month 2. “Good responders” were defined as those who showed complete resolution of subretinal and/or intraretinal fluid at month 3 after the loading injections, whereas “poor-responders” were defined as those who showed persistent retinal fluids on optical coherence tomography (OCT) at month 3 after the loading injections. Best-corrected visual acuity, indocyanine green angiography, and spectral domain-OCT findings between the 2 groups at baseline were analyzed.

 
Results
 

Mean age was 68.2 ± 9.7 years and the mean follow-up period was 27 ± 21 months. The mean subfoveal choroidal thickness was 273 ± 117 μm and choroidal vascular hyperpermeability was observed in 35 eyes (53.0%). Thirty-three eyes (50%) showed good response to treatment, and a thinner subfoveal choroid at baseline significantly correlated with favorable treatment response (P=0.024). However, there was no significant relationship between treatment response and choroidal vascular hyperpermeability (P=0.999).

 
Conclusions
 

Patients who achieved complete resolution of macular exudation after 3 loading injections of anti-VEGF agents had significantly thinner subfoveal choroidal thickness.  

 
Fluorescein angiography (top left) and indocyanine green angiography (top right) show polypoidal choroidal vasculopathy. At baseline, SD-OCT (bottom left) shows that the subretinal fluid and subfoveal choroidal thickness was 176 μm. After 3 loadings of intravitreal ranibizumab injections, no fluid was detected (bottom right).
 
Fluorescein angiography (top left) and indocyanine green angiography (top right) show polypoidal choroidal vasculopathy. At baseline, SD-OCT (bottom left) shows that the subretinal fluid and subfoveal choroidal thickness was 176 μm. After 3 loadings of intravitreal ranibizumab injections, no fluid was detected (bottom right).
 
 
Fluorescein angiography (top left) and indocyanine green angiography (top right) show polypoidal choroidal vasculopathy. At baseline, SD-OCT (bottom left) shows that the subretinal fluid and subfoveal choroidal thickness was 358 μm. After 3 loadings of intravitreal ranibizumab injections, subretinal fluid still remained (bottom right).
 
Fluorescein angiography (top left) and indocyanine green angiography (top right) show polypoidal choroidal vasculopathy. At baseline, SD-OCT (bottom left) shows that the subretinal fluid and subfoveal choroidal thickness was 358 μm. After 3 loadings of intravitreal ranibizumab injections, subretinal fluid still remained (bottom right).

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×